3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Carcinoma, Hepatocellular
4
Uterine Cervical Neoplasms
3
Prostatic Neoplasms
3
Uterine Cervical Dysplasia
2
Thyroid Nodule
2
Sarcoma
2
Papillomavirus Infections
2
Melanoma
2
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Spinal Cord Compression
1
Recurrence
1
Prostatic Hyperplasia
1
Precancerous Conditions
1
Pancreatic Ductal Adenocarcinoma
1
Neoplasms, Unknown Primary
1
Neoplasms by Site
1
Neoplasms
1
Liver Neoplasms
1
Hyperthyroidism
1
HIV Infections
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Gastrointestinal Neoplasms
1
Interventions
Pemetrexed
9
Nivolumab
8
Cisplatin
8
Carboplatin
8
pembrolizumab
7
130-nm albumin-bound paclitaxel
7
Gemcitabine
6
padeliporfin
5
durvalumab
5
Paclitaxel
5
Bevacizumab
5
palbociclib
4
napabucasin
4
atezolizumab
4
Irinotecan
4
Fulvestrant
4
Fluorouracil
4
Cyclophosphamide
4
ribociclib
3
osimertinib
3
cobimetinib
3
alectinib
3
abemaciclib
3
Trastuzumab
3
Sunitinib
3
Radiosurgery
3
Drug Therapy
3
Docetaxel
3
Cetuximab
3
Anastrozole
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms by Site
×
Transurethral Resection of Prostate
×
Clear all
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled